首页> 美国卫生研究院文献>Journal of the Boston Society of Medical Sciences >CD28-B7-Mediated T Cell Costimulation in Chronic Cardiac Allograft Rejection
【2h】

CD28-B7-Mediated T Cell Costimulation in Chronic Cardiac Allograft Rejection

机译:CD28-B7介导的慢性同种异体移植排斥反应中的T细胞共刺激。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Provision of adequate T cell costimulation is critical for the development of acute and chronic allograft rejection. We have previously reported that early blockade of CD28-B7 T cell costimulation prevents the development of graft arteriosclerosis, in the LEW into F344 rat cardiac transplant model. In this study, we used the same model to examine the requirement for CD28-B7-mediated T cell costimulation in the progression of established chronic rejection and examined the individual roles of B7–1 (CD80) and B7–2 (CD86) costimulatory molecules. Late blockade of CD28-B7 T cell costimulation by the fusion protein CTLA4Ig, which binds both CD80 and CD86, attenuated the development of transplant arteriosclerosis, mononuclear cell infiltration, and parenchymal fibrosis in this model. Selective blockade of CD80 using the mutant fusion protein Y100F was as effective as CTLA4Ig in this regard. In contrast to CTLA4Ig, blockade of CD80 alone by Y100F was ineffective at preventing early graft loss and prolonging graft survival when given early after transplantation. This study is the first to demonstrate that late blockade of CD28-B7 T cell costimulation interrupts chronic cardiac allograft rejection, and it indicates the importance of continued T cell activation in this process. This study further defines functional differences between CD80 and CD86 costimulatory molecules in vivo.
机译:提供足够的T细胞共刺激对于急性和慢性同种异体排斥反应的发展至关重要。我们先前曾报道过,在LEW进入F344大鼠心脏移植模型中,早期阻断CD28-B7 T细胞的共刺激作用可防止移植动脉硬化的发展。在这项研究中,我们使用相同的模型检查了CD28-B7介导的T细胞共刺激在已建立的慢性排斥反应中的需求,并研究了B7-1(CD80)和B7-2(CD86)共刺激分子的个体作用。在该模型中,融合蛋白CTLA4Ig(同时结合CD80和CD86)对CD28-B7 T细胞的共刺激的晚期阻滞减弱了移植动脉硬化,单核细胞浸润和实质纤维化的发展。在这方面,使用突变融合蛋白Y100F选择性阻断CD80与CTLA4Ig一样有效。与CTLA4Ig相比,当在移植后早期给予Y100F单独阻断CD80不能有效防止早期移植物丢失和延长移植物存活。这项研究是第一个证明CD28-B7 T细胞共刺激的晚期阻断会中断慢性心脏同种异体移植排斥反应的研究,这表明持续T细胞活化在此过程中的重要性。这项研究进一步定义了体内CD80和CD86共刺激分子之间的功能差异。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号